Its a common question because obesity, insulin resistance, type 2 diabetes, and hypertension often occur together
Studies that include patients who are considered at-risk (i.e., diabetics, cardiac, elderly, etc.) and are currently taking GLP-1 RAs should also be performed as these patients may have compounding risk during the perioperative period which may make them more susceptible to complications related to GLP-1 use (Santos et al
Do not change or stop an antihypertensive medication on your own initiative
Conclusion The SURMOUNT-OSA trials mark a significant milestone in the treatment of obstructive sleep apnea and obesity
The procedures of animal study were approved by the Institutional Animal Care and Use Committee (IACUC2017O04) of National Laboratory Animal Center, National Applied Research Laboratories, Taiwan